摘要
目的探讨ＤＮＡ拓扑异构酶Ⅱ（ＴＯＰＯⅡ）与膀胱肿瘤的病理分级、临床分期及多药耐药的关系。方法应用抗ＤＮＡ拓扑异构酶Ⅱ单克隆抗体ＳＷＴ３Ｄ１对６４例膀胱移行细胞癌进行免疫组化研究。结果ＤＮＡ拓扑异构酶Ⅱ增殖指数随肿瘤细胞分级增高而逐步升高，Ｇ１、Ｇ２、Ｇ３分别为（５６±１７）％、（１３７±１０２）％、（２３２±１５７）％（Ｐ＜００５），ＴＯＰＯⅡ在膀胱癌的表达与临床分期和复发无相关性（Ｐ＞００５）。结论ＴＯＰＯⅡ指数与膀胱癌的生物学特性相关。
Objective To investigate the patterns of expression of topoisomerase Ⅱ in patients with urinary bladder cancer undergone cystectomy. Methods 64 formalin fixed cystectomy specimens were stained immunohistochemically for topoisomerase Ⅱ using SWT3D1 monoclonal antibody after pressure cooker heating of tissue sections and correlated the results with tumor grade,stage and recurrence. Results Topoisomerase Ⅱ LI(labelling index )increased with pathological grade.Topoisomerase Ⅱ LI of G 1、G 2、G 3 were (5 6±1 7)%、(13 7±10 2)%、(23 2±15 7)%,repectively ( P <0 05). Topoisomerase Ⅱ LI did not correlate with the recurrence and clinical stages( P >0.05). Conclusions Expression of topoisomeraseⅡ is related to poor prognostic factors.Immunohistochemical assessment of topoisomerase Ⅱ expression in transitional tumor of bladder might be useful for tailoring chemotherapy with topoisomerase Ⅱ inhibitors.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
1999年第1期25-26,共2页
Chinese Journal of Urology
